ORUKA THERAPEUTICS INC (ORKA) Stock Price, Forecast & Analysis
NASDAQ:ORKA • US6876041087
ORKA Key Statistics, Chart & Performance
The current stock price of ORKA is 32.21 USD. In the past month the price decreased by -0.89%. In the past year, price increased by 188.1%.
ORKA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ORKA. When comparing the yearly performance of all stocks, ORKA is one of the better performing stocks in the market, outperforming 97.28% of all stocks.
ORKA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORKA. No worries on liquidiy or solvency for ORKA as it has an excellent financial health rating, but there are worries on the profitability.
ORKA Financial Highlights
Over the last trailing twelve months ORKA reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 66.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.96% | ||
| ROE | -20.88% | ||
| Debt/Equity | 0 |
ORKA Forecast & Estimates
20 analysts have analysed ORKA and the average price target is 57.98 USD. This implies a price increase of 80.02% is expected in the next year compared to the current price of 32.21.
ORKA Ownership
ORKA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ORKA
Company Profile
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 28 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Company Info
ORUKA THERAPEUTICS INC
855 Oak Grove Ave., Suite 100
Menlo Park CALIFORNIA US
Employees: 28
Phone: 13026587581
ORUKA THERAPEUTICS INC / ORKA FAQ
Can you describe the business of ORUKA THERAPEUTICS INC?
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 28 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
What is the current price of ORKA stock?
The current stock price of ORKA is 32.21 USD. The price decreased by -1.32% in the last trading session.
Does ORKA stock pay dividends?
ORKA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ORKA stock?
ORKA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in ORUKA THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ORKA.
What is the market capitalization of ORKA stock?
ORUKA THERAPEUTICS INC (ORKA) has a market capitalization of 1.56B USD. This makes ORKA a Small Cap stock.
What is the ownership structure of ORUKA THERAPEUTICS INC (ORKA)?
You can find the ownership structure of ORUKA THERAPEUTICS INC (ORKA) on the Ownership tab.